Avasarala, J. (2017). Anti-CD20 Cell Therapies in Multiple Sclerosis—A Fixed Dosing Schedule for Ocrelizumab is Overkill. Drug Target Insights, 11(1). https://doi.org/10.33393/dti.2017.1367